Alert button
Picture for Arian R. Jamasb

Arian R. Jamasb

Alert button

Multi-State RNA Design with Geometric Multi-Graph Neural Networks

May 25, 2023
Chaitanya K. Joshi, Arian R. Jamasb, Ramon Viñas, Charles Harris, Simon Mathis, Pietro Liò

Figure 1 for Multi-State RNA Design with Geometric Multi-Graph Neural Networks
Figure 2 for Multi-State RNA Design with Geometric Multi-Graph Neural Networks
Figure 3 for Multi-State RNA Design with Geometric Multi-Graph Neural Networks
Figure 4 for Multi-State RNA Design with Geometric Multi-Graph Neural Networks

Computational RNA design has broad applications across synthetic biology and therapeutic development. Fundamental to the diverse biological functions of RNA is its conformational flexibility, enabling single sequences to adopt a variety of distinct 3D states. Currently, computational biomolecule design tasks are often posed as inverse problems, where sequences are designed based on adopting a single desired structural conformation. In this work, we propose gRNAde, a geometric RNA design pipeline that operates on sets of 3D RNA backbone structures to explicitly account for and reflect RNA conformational diversity in its designs. We demonstrate the utility of gRNAde for improving native sequence recovery over single-state approaches on a new large-scale 3D RNA design dataset, especially for multi-state and structurally diverse RNAs. Our code is available at https://github.com/chaitjo/geometric-rna-design

Viaarxiv icon

Utilising Graph Machine Learning within Drug Discovery and Development

Dec 09, 2020
Thomas Gaudelet, Ben Day, Arian R. Jamasb, Jyothish Soman, Cristian Regep, Gertrude Liu, Jeremy B. R. Hayter, Richard Vickers, Charles Roberts, Jian Tang, David Roblin, Tom L. Blundell, Michael M. Bronstein, Jake P. Taylor-King

Figure 1 for Utilising Graph Machine Learning within Drug Discovery and Development
Figure 2 for Utilising Graph Machine Learning within Drug Discovery and Development
Figure 3 for Utilising Graph Machine Learning within Drug Discovery and Development
Figure 4 for Utilising Graph Machine Learning within Drug Discovery and Development

Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development. After introducing key terms and modelling approaches, we move chronologically through the drug development pipeline to identify and summarise work incorporating: target identification, design of small molecules and biologics, and drug repurposing. Whilst the field is still emerging, key milestones including repurposed drugs entering in vivo studies, suggest graph machine learning will become a modelling framework of choice within biomedical machine learning.

* 19 pages, 8 figures 
Viaarxiv icon

Message Passing Neural Processes

Sep 29, 2020
Ben Day, Cătălina Cangea, Arian R. Jamasb, Pietro Liò

Figure 1 for Message Passing Neural Processes
Figure 2 for Message Passing Neural Processes
Figure 3 for Message Passing Neural Processes
Figure 4 for Message Passing Neural Processes

Neural Processes (NPs) are powerful and flexible models able to incorporate uncertainty when representing stochastic processes, while maintaining a linear time complexity. However, NPs produce a latent description by aggregating independent representations of context points and lack the ability to exploit relational information present in many datasets. This renders NPs ineffective in settings where the stochastic process is primarily governed by neighbourhood rules, such as cellular automata (CA), and limits performance for any task where relational information remains unused. We address this shortcoming by introducing Message Passing Neural Processes (MPNPs), the first class of NPs that explicitly makes use of relational structure within the model. Our evaluation shows that MPNPs thrive at lower sampling rates, on existing benchmarks and newly-proposed CA and Cora-Branched tasks. We further report strong generalisation over density-based CA rule-sets and significant gains in challenging arbitrary-labelling and few-shot learning setups.

* 18 pages, 6 figures. The first two authors contributed equally 
Viaarxiv icon